Compass Pathways PLC Sponsored ADR $CMPS Stock Acquired by Candriam S.C.A.

Candriam S.C.A. increased its stake in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 18.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,510,695 shares of the company's stock after purchasing an additional 236,417 shares during the period. Candriam S.C.A. owned 1.09% of Compass Pathways worth $18,862,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Eagle Health Investments LP increased its position in Compass Pathways by 35.6% during the first quarter. Eagle Health Investments LP now owns 2,060,427 shares of the company's stock worth $11,394,000 after buying an additional 541,039 shares in the last quarter. Orbimed Advisors LLC purchased a new stake in shares of Compass Pathways in the first quarter valued at $6,363,000. Affinity Asset Advisors LLC boosted its stake in shares of Compass Pathways by 454.2% during the first quarter. Affinity Asset Advisors LLC now owns 1,108,483 shares of the company's stock valued at $6,130,000 after acquiring an additional 908,483 shares during the last quarter. CenterBook Partners LP boosted its stake in shares of Compass Pathways by 454.1% during the third quarter. CenterBook Partners LP now owns 695,943 shares of the company's stock valued at $8,658,000 after acquiring an additional 570,349 shares during the last quarter. Finally, Eversept Partners LP acquired a new stake in shares of Compass Pathways during the first quarter valued at $3,749,000. Hedge funds and other institutional investors own 46.19% of the company's stock.

Compass Pathways Price Performance

CMPS opened at $8.61 on Monday. Compass Pathways PLC Sponsored ADR has a 12 month low of $4.88 and a 12 month high of $15.87. The business has a 50-day moving average of $12.32 and a two-hundred day moving average of $10.41. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.50 and a quick ratio of 1.50. The stock has a market capitalization of $1.19 billion, a price-to-earnings ratio of -2.47 and a beta of 2.43.

Compass Pathways (NASDAQ:CMPS - Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.08. On average, research analysts expect that Compass Pathways PLC Sponsored ADR will post -0.83 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on the company. BTIG Research reiterated a "buy" rating and set a $25.00 price objective on shares of Compass Pathways in a research report on Tuesday, November 3rd. HC Wainwright decreased their price target on shares of Compass Pathways from $70.00 to $65.00 and set a "buy" rating on the stock in a research note on Friday, August 7th. B. Riley Financial lifted their price target on shares of Compass Pathways from $17.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Oppenheimer reiterated an "outperform" rating and set a $20.00 price target on shares of Compass Pathways in a report on Tuesday, November 3rd. Finally, Royal Bank Of Canada reissued an "outperform" rating on shares of Compass Pathways in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $23.14.

About Compass Pathways

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company's lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.

Want to see what other hedge funds are holding CMPS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.